The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis

Современная ревматология

L. A. Muravyeva¹  Yu. V. Muravyev² 

[1] Khimki Central Clinical Hospital;V.A. Nasonova Research Institute of Rheumatology;

关键词: rheumatoid arthritis;    laboratory monitoring;    disease-modifying antirheumatic drugs;    biological agents;   

DOI  :  10.14412/1996-7012-2018-3-120-123

来源: DOAJ

【 摘 要 】

The paper discusses the problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs) in patients with rheumatoid arthritis (RA). Due to the risk of adverse reactions, in particular to that of cardiovascular diseases, hepatotoxicity, hematological disorders, deterioration of renal function, infections, and bleeding caused by the use of DMARDs and BAs, recommendations are needed to have a list of tests for laboratory monitoring during this therapy and the frequency of their implementation in patients with RA.

【 授权许可】

Unknown